

DIMERIX APPOINTS NEW CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

MELBOURNE, Australia, 6th May 2019: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, announced the appointment of Mr Hamish George, of Bio101Group Pty Ltd, as Chief Financial Officer and Company Secretary, effective 6th May 2019. Hamish replaces Perth based Ian Hobson, who has been the Company Secretary for Dimerix since 2014.

Hamish has experience in providing financial advice and CFO services to businesses ranging from small start-ups to large established businesses with turnover of over \$50 million. He brings expertise in areas including financial/management reporting, Company Secretarial, cashflow management, taxation including (R&D Tax Incentive), Company Establishments, company valuations, budgeting and forecasting. Hamish is also a member of the senior management team at Bio101, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector.

“I am delighted to appoint Hamish to the CFO and company Secretary role. Hamish brings a wealth of financial and corporate knowledge to the role which will be invaluable as we continue our strategy to strengthen and grow our businesses through operational efficiencies and corporate development,” said Dr Nina Webster, Dimerix CEO and Managing Director. “I am confident Hamish will be a strong addition to the Dimerix team and I look forward to growing the business further with Hamish’s support. The Board and I would like to thank Ian Hobson for his outstanding contribution to the Company over the past five years and wish him every success for the future.”

Hamish holds a Bachelor of Commerce from the University of Melbourne, a Diploma in Financial Planning from Kaplan Professional, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

—END—

**Dimerix is a biopharmaceutical company
developing innovative new therapies in
areas with unmet medical needs.**

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com



About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for kidney disease. DMX-200 has granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all trial endpoints were achieved. In a subsequent subgroup analysis, significant clinical efficacy signals were seen in the diabetic group.

DMX-200 administered to patients already taking irbesartan reduced proteinuria levels by a further 36%. This reduction in proteinuria is highly correlated with improved renal function and delay in kidney failure and dialysis. The compelling results from this study prompted the decision to initiate two different clinical trials in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS).

FSGS is a serious and rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and kidney failure and for which there is a recognised medical need for a new or improved treatment. FSGS affects both children and adults.

DMX-200 for FSGS has been granted Orphan Drug Designation by the FDA and EMA. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and an abbreviated regulatory pathway to approval.

**Dimerix is a biopharmaceutical company
developing innovative new therapies in
areas with unmet medical needs.**

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com